Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Total Debt
Short-term and long-term borrowings combined.
Vor Biopharma Inc.NASDAQ: VOR
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 90.5% from a year ago
Total debt stood at $2.94M at the end of Q1 FY2026, down 90.5% from a year earlier and down 2.0% from the prior quarter. Over 3 fiscal years it compounded at -57.4% a year.
Context
- Total debt amounted to 0.6% of total assets at the end of Q1 FY2026, down 27.6 pp from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -90.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 3M USD
- Year-over-year change
- -90.6%
- 4-year CAGR
- -36.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3M | -90.6% |
| FY2024 | 2024-12-31 | 31.83M | -10.7% |
| FY2023 | 2023-12-31 | 35.66M | -8.4% |
| FY2022 | 2022-12-31 | 38.91M | +116.0% |
| FY2021 | 2021-12-31 | 18.01M | — |
Total Debt vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's Mar 2026 total debt of $2.94M is the lowest of the 10 companies compared; the peer median is $75.33M.
- Its year-over-year change of -90.5% is the lowest of 10, against a peer median of -7.9%.
- Total debt amounts to 0.6% of total assets for VOR, versus a peer median of 20.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $779.83M | +93.1% | +17.4% | 30.5% | |
| Mar 2026 | $80.49M | -32.5% | -10.6% | 10.6% | |
| Mar 2026 | $79.96M | -74.3% | +143.8% | 15.2% | |
| Mar 2026 | $76.79M | -7.9% | -10.7% | 27.0% | |
| Mar 2026 | $75.33M | -17.5% | -10.0% | 20.2% | |
| Mar 2026 | $75M | -5.0% | -2.7% | 20.2% | |
| Mar 2026 | $71.97M | +131.2% | +20.4% | 48.2% | |
| Mar 2026 | $48.03M | -8.8% | -4.1% | 14.7% | |
| Mar 2026 | $24.76M | -2.3% | +2.8% | 8.7% | |
| Mar 2026 | $2.94M | -90.5% | -57.4% | 0.6% | |
| Peer median (excluding VOR) | $75.33M | -7.9% | -2.7% | 20.2% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 119.8M | 57.71M | 31.36M | 81.95M | 396.49M |
| Short-term Investments | 87.67M | 172.54M | 105.82M | 9.98M | 58.72M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.09M | 2.34M | 475K | 380K | 1.75M |
| Total Current Assets | 214.4M | 236.95M | 140.8M | 96.51M | 458.11M |
| Property, Plant & Equipment (Net) | 22.52M | 57.08M | 50.1M | 41.59M | 3.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 2.41M | 2.41M | 0 | 0 |
| Tax Assets | 0 | 0 | 11.7M | 0 | 0 |
| Other Non-current Assets | 5.67M | 2.93M | 4.81M | 4.8M | 2.55M |
| Total Non-current Assets | 28.19M | 62.42M | 69.03M | 46.38M | 6.02M |
| Total Assets | 242.59M | 299.37M | 209.83M | 142.89M | 464.13M |
| Account Payables | 1.55M | 1.77M | 815K | 1.51M | 5.13M |
| Short-term Debt | 0 | 0 | 3.83M | 0 | 280K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 434K | 4.95M | 4.97M | 6.21M | 15.33M |
| Total Current Liabilities | 10.15M | 13.12M | 15.57M | 18.61M | 25.17M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 11.7M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 600.55M |
| Total Non-current Liabilities | 16.17M | 35.64M | 43.53M | 27.62M | 603.27M |
| Total Liabilities | 26.33M | 48.76M | 59.1M | 46.23M | 628.44M |
| Common Stock | 4K | 7K | 7K | 13K | 18K |
| Retained Earnings | (130.12M) | (222.22M) | (340.08M) | (456.99M) | (1.15B) |
| Accumulated OCI | 0 | (770K) | (77K) | 22K | 41K |
| Other Stockholders Equity | (1K) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 216.26M | 250.61M | 150.72M | 96.66M | (164.31M) |
| Total Debt | 18.01M | 38.91M | 35.66M | 31.83M | 3M |
| Net Debt | (101.79M) | (18.79M) | 4.3M | (50.12M) | (393.49M) |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.